Kyverna Therapeutics, Inc. KYTX Payments for finance leases
Payments for finance leases at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeasePrincipalPayments.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s payments for finance leases.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s payments for finance leases?
- Kyverna Therapeutics, Inc. (KYTX) reported payments for finance leases of $86K in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s payments for finance leases changed year-over-year?
- Kyverna Therapeutics, Inc.'s payments for finance leases decreased by 74.8% year-over-year, from $341K to $86K.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s payments for finance leases?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s payments for finance leases has grown at a 1.8% compound annual growth rate (CAGR), from $780K to $808K.
- What does payments for finance leases mean?
- Principal payments on finance lease obligations, reducing the lease liability on the balance sheet.